

1 **Title page**

2 **Title**

3 Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource
4 settings

5 **Short title:** Simplified HPV genotyping test for low-resource settings

6 **Authors:** Kanan T. Desai^{1,2}, Kayode O. Ajenifuja³, Clement A. Adepiti³, Federica Inturrisi¹, Casey
7 Dagnall^{1,4}, Amanda C. Hoffman^{1,4}, Didem Egemen¹, Julia C. Gage¹, Nicolas Wentzensen¹, Silvia
8 de Sanjose^{1,5}, Mark Schiffman¹

9 **Author's affiliation:**

10 ¹National Cancer Institute, Rockville, MD, USA

11 ²Norwalk Hospital Internal Medicine Residency Program, Norwalk, CT, USA

12 ³Obafemi Awolowo University, Ile-Ife, Nigeria

13 ⁴Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research,
14 Leidos Biomedical Research, Inc., Frederick, MD, USA

15 ⁵ISGlobal, Barcelona, Spain

16 **Corresponding Author:** Federica Inturrisi (f.inturrisi@outlook.com)

17 **Keywords:** Cervical cancer screening, HPV testing, HPV genotyping, point-of-care, LMICs

18 **Abbreviations:** CI, confidence interval; CIN, cervical intraepithelial neoplasia; CGR, Center for
19 Cancer Genomics Laboratory; DNA, deoxyribonucleic acid; HPV, human papillomavirus; IARC,
20 International Agency for Research on Cancer; IP, intellectual property; LBC, liquid-based
21 cytology; LMIC, low- and middle-income country; NCI, National Cancer Institute; NIH, National
22 Institutes of Health; PAVE, HPV-Automated Visual Evaluation; PCR, polymerase chain reaction;
23 RS, risk stratification; RUO, research-use-only; SPSS, statistical package for the social sciences;
24 WHO, World Health Organization.

25

26 **Main text word count:** 3860 words

27 **Abstract word count:** 300 words

28 **Abstract**

29 **Introduction:**

30 Human papillomavirus (HPV) genotype predicts cervical cancer risk, and genotyping could help
31 guide management of HPV positives as part of cervical screening. An isothermal amplification
32 HPV extended genotyping test (ScreenFire HPV RS assay) can assay up to 96 controls/samples in
33 one hour plus preparation time. A novel format with pre-aliquoted reagents and an anti-
34 contamination component (Zebra BioDome™) could simplify the HPV testing process by
35 substantially reducing the assay preparation time and the chances of post-amplification
36 contamination. We validated Zebra BioDome formulation prior to its clinical use.

37 **Methods:**

38 Residual provider-collected cervical samples (n=450) from a population-based study in rural
39 Nigeria were retested with ScreenFire, once using the standard assay version (liquid reagents
40 combined onsite) and twice with Zebra BioDome. HPV results with adequate DNA (N=427) were
41 analyzed channel-by-channel and using the cervical cancer risk-based hierarchy of HPV type
42 channels (HPV16, else 18/45, else 31/33/35/52/58, else 39/51/56/59/68, else high-risk HPV
43 negative) to evaluate Zebra BioDome repeatability and accuracy against the standard version.

44 **Results:**

45 Zebra BioDome reduced the number of pipetting steps to run the ScreenFire HPV assay.
46 Following amplification, the BioDome material formed a sealant layer above the reaction
47 components. Zebra BioDome had excellent repeatability and agreement with the standard
48 version, both at the channel-specific analysis [positive percent agreement between 88.4%
49 (HPV39/51/56/59/68) and 100% (HPV16); negative percent agreement between 97.8%
50 (HPV31/33/35/52/58) and 100% (HPV39/51/56/59/68)] and hierarchical analysis (overall
51 agreement 97.2%).

52 **Conclusions:**

53 The assay version utilizing Zebra BioDome performed similarly to the previously validated
54 standard version of the ScreenFire HPV assay and is now undergoing field evaluation. This
55 solution has the potential to reduce assay preparation time and risk of contamination,
56 providing a simpler, low-cost, near-point-of-care HPV testing and extended genotyping solution

- 57 for cervical screening in lower-resource settings. Potential application of Zebra BioDome
58 technology to other DNA amplification assays should be considered.

59 **Main text**

60 **Introduction**

61 Cervical cancer rates and deaths tend to be highest in regions with limited resources (1). The
62 World Health Organization (WHO) call to eliminate cervical cancer globally promotes human
63 papillomavirus (HPV) vaccination, HPV-based screening during mid-adulthood, and treatment of
64 both precancerous and cancerous conditions (2). Highly sensitive HPV testing of self-collected
65 samples is being promoted worldwide (3), because of the crucial role of HPV in the
66 development of cervical cancer (4), and the pressing need to screen many millions of women. It
67 is impractical to treat every infected woman in high-prevalence areas, because HPV infections
68 are extremely common and often benign. Most HPV infections are controlled by the immune
69 system within 1 to 2 years of detection, and only persistently detectable infections lead to
70 precancer and cancer (4). Because HPV detection on population screening can be very common,
71 and follow-up to distinguish persistence is often impractical, a triage test to identify biomarkers
72 of persistent/progressive infections is necessary for prioritization of care by need. HPV typing is
73 a promising means of triage, because the likelihood of progression depends on the HPV type
74 and varies significantly among the 13 high-risk HPV types (5,6) classified by the International
75 Agency for Research on Cancer (IARC) as Group 1 (known carcinogens) or Group 2A (probable
76 carcinogens) (7). Risk-based extended HPV typing is proposed to stratify HPV-positive women
77 according to their risk of developing cervical cancer and to guide clinical management (6).

78 An isothermal DNA amplification technology-based ScreenFire HPV risk stratification (RS) assay
79 (Atila Biosystems Inc., Sunnyvale, CA, USA) can provide extended genotyping for 13 high-risk
80 HPV types in the four established risk channels: 16, 18/45, 31/33/35/52/58, and
81 39/51/56/59/68 (8,9). It was designed to support clinical management according to the risk of
82 cervical cancer associated with the grouped types, hence the emphasis on risk stratification, in
83 which the highest-risk positive channel is reported when multiple concurrent infections are
84 present. It is relatively rapid and low-cost, making it suitable for extended HPV genotyping
85 beyond high-resource settings. Its clinical accuracy has already been shown (8–11) and the
86 assay is currently undergoing field validation as part of the HPV-Automated Visual Evaluation

87 (PAVE) protocol in nine low- and middle-income countries (LMICs) worldwide (12). Two aspects
88 of performing the ScreenFire HPV RS assay emerged during the validation to date and are
89 addressed here: the need to further decrease the time and manual handling
90 needed to run the assay, particularly during assay preparation phase, and the risk of laboratory
91 contamination. Despite being a simple assay, the ScreenFire HPV RS test in its current format
92 still requires that a trained laboratory technician carry out a number of preparatory steps:
93 thawing reagents, preparing the master mix (by combining reaction mix and primer mix),
94 dispensing the master mix into reaction tubes, and then adding the sample (Figure 1A). These
95 steps involve pipetting small volumes of reagents and samples, demanding careful attention to
96 detail and increasing the risk of human error, cross-contamination, and variability in results.
97 Moreover, these steps add to the overall time required for HPV testing, making single-day
98 screening strategies more difficult.

99 Moreover, like any other DNA amplification technique (13), ScreenFire HPV RS assay is
100 susceptible to contamination of the laboratory environment by amplified products. The
101 problem arises because the post-amplification concentration of amplicons in a positive
102 sample/control can reach 100-1000 billion copies per microliter. If the tube content is not
103 strictly contained after amplification, the high concentration of amplicons can contaminate
104 laboratory surfaces, equipment, pipettors, and personal protective gear like gloves and
105 laboratory coats. Identifying and cleaning up this contamination is time-consuming and
106 resource-intensive, both in terms of labor and money, and it precludes HPV testing activities
107 until full decontamination has been verified.

108 To reduce the number of pipetting steps and mitigate the risk of contamination, the assay's
109 manufacturer Atila BioSystems developed an assay format with pre-aliquoted reagents and an
110 anti-contamination component, known as 'Zebra BioDome™'. This format removes the need for
111 preparation and dispensing of the master mix, only requiring the addition of the lysate to the
112 Zebra BioDome tubes (Figure 1B) as the two components of the master mix are suspended
113 between gel matrix layers. The gel matrix melts during amplification enabling the mixing of

114 sample and reagents and solidifies again at the top of the reaction volume during cooling, thus
115 creating a physical barrier for the amplified products (Figure 1C).

116 This article aims to independently validate the Zebra BioDome version of the ScreenFire HPV RS
117 assay by comparing it with the established standard liquid version of the assay and assessing its
118 repeatability.

119

120 **Materials and Methods**

121 ***Study population and design***

122 The present study drew from 1,339 residual cervical samples stored frozen in PreservCyt
123 solution (Hologic, Marlborough, MA, USA), collected by providers from a population-based
124 screening project in rural Nigeria (Project Itoju) involving women aged 16 to 88 years (mean
125 [standard deviation] = 44.0 [15.8]). The methodology of the Project Itoju has been detailed
126 elsewhere (14). In brief, between 2009 and 2010, approximately 1,420 eligible women—who
127 were not pregnant, were sexually active, had not undergone a hysterectomy, were at least 15
128 years old, and had been residing in their household for more than 3 months—were invited from
129 homes in the village of Irun, Nigeria. Participants in the research effort provided written
130 informed consent. During the screening, locally trained nurses conducted cervical examinations
131 and collected samples using a broom-type device and an endocervical brush, which were then
132 placed in PreservCyt for liquid-based cytology (LBC) and HPV testing.

133 One milliliter aliquots of the frozen residual cytology samples were tested in the United States
134 (Albert Einstein Cancer Center) for HPV using an AmpliTaq Gold MY09-MY11 polymerase chain
135 reaction (PCR)-based test that included additional type-specific primers, and primers to amplify
136 a cellular beta-globin fragment as an internal control for amplification as previously
137 described (15). PCR products were genotyped with dot-blot hybridization using type-specific
138 probes for 13 high-risk and >20 other HPV types, using a semi-quantitative measure of signal
139 strength (1-5 from lowest to highest) as a proxy of viral load (16). Of note, the PCR signal
140 strength variable (1-5) is not strictly linear, in that a signal strength of 5 has no upper bound

141 and is, on average, particularly strong. Samples were also tested for HPV16 and HPV18 using a
142 research-use-only (RUO) HPV DNA test, the Luminex assay.

143 Out of the 1,339 residual samples, valid (i.e., adequate DNA) HPV results at the AmpliTaQ Gold
144 MY09-MY11 PCR were obtained for 1,305 samples. A small subset (n = 8) was unblinded and
145 sent to Atila BioSystems for updating the AmpFire assay chemistry to the ScreenFire RS HPV
146 assay with its emphasis on sensitive detection of the most high-risk HPV types (8). Of the
147 remaining 1,297 masked samples with valid results, we selected all 356 samples that tested
148 positive for any HPV types (including low-risk types) by either PCR or HPV16/18 Luminex.
149 Additionally, we randomly chose 100 of 941 specimens that tested negative for all HPV types
150 (including low-risk) by both PCR and Luminex. These 456 samples were previously used to
151 redesign and validate the ScreenFire HPV RS assay in its current standard format (8). Out of the
152 456 samples, six were found to have insufficient residual material (i.e., no more volume),
153 leaving 450 usable samples.

154 These same 450 samples were retested with ScreenFire HPV RS assay using both the standard
155 (9) and Zebra BioDome versions of the assay. Testing using the standard version was conducted
156 at the US National Cancer Institute's (NCI) Cancer Genomics Research (CGR) laboratory with
157 visiting Atila BioSystems laboratory scientists. Testing using the Zebra BioDome version was
158 conducted at the Atila BioSystems Laboratory by Atila BioSystems scientists. The scientists were
159 blinded to prior testing results and had no role in the analysis or reporting of the experiments.

160 ***ScreenFire HPV testing***

161 As per manufacturer's protocol, ScreenFire HPV RS assay can be used with dry swab samples,
162 cervical cell suspension, FFPE slice samples, and purified DNA samples. For the work presented
163 here, the protocol for cervical cell suspension was used, plus pre-processing steps to prepare
164 the frozen residual specimens. Initially, 1 mL of cervical cell suspension in PreservCyt was
165 transferred to a 1.5 mL tube and centrifuged at maximum speed for 15 minutes. The
166 supernatant was discarded, and 100 μ L of 1X lysis buffer was added to the pellet. The mixture
167 was vortexed thoroughly to resuspend the cells. The resuspended cell pellets were then

168 transferred to 96-well PCR plates, incubated at 95°C for 15 minutes, allowed to cool to room
169 temperature, and stored at -20°C for future use.

170 The plates were thawed at room temperature prior to testing with ScreenFire HPV RS assay.
171 This was done twice on one Powergene 9600 real-time PCR machine, once using the standard
172 liquid version and once using the Zebra BioDome version, and once on a second Powergene
173 machine using the Zebra BioDome version.

174 For testing with the standard liquid version, 5 µL of the prepared specimen (lysate) was
175 combined with 20 µL of freshly prepared master mix (containing reaction mix and primer mix)
176 in a 96-well PCR plate using a pipette. For testing with the Zebra BioDome version, 10 µL of the
177 lysate was added to each well using the technique described below. Positive and negative
178 template controls were included in each run. The plates or tube strips were sealed or capped,
179 gently vortexed, and centrifuged to ensure that all liquid settled at the bottom of the wells.

180 The plates or Zebra BioDome tube strips were then placed into the Powergene 9600 real-time
181 PCR machines, set to the isothermal program mode (60°C for 60 cycles of 1 minute each).
182 Fluorescence signals were detected using CY5 for the HPV16 channel, ROX for the HPV18/45
183 channel, CY5.5 for the HPV31/33/35/52/58 channel, FAM for the HPV39/51/56/59/68 channel,
184 and HEX for the human beta-globin gene as the internal control channel. A sample was deemed
185 positive for an HPV type (group) if a signal was detected in the corresponding HPV channel
186 within 60 minutes, regardless of the HEX channel signal. If no signal was detected in any of the
187 HPV channels within 60 minutes, a signal in the HEX channel was required for a certain sample
188 to be considered a valid HPV negative. If no signal was detected in any of the channels including
189 the HEX channel, a sample was considered invalid suggesting inadequate DNA in the reaction.

190 ***Zebra BioDome technology***

191 Zebra BioDome is a proprietary format for isothermal amplification assays by Atila BioSystems.
192 It features layers of reaction mix and primer mix separated by the BioDome anti-contamination
193 gel matrix, with an additional BioDome layer on top for stability and containment. This assay

194 format comes as prepacked reaction tube strips covered by an adhesive film to prevent
195 evaporation (Figure 1C-i).

196 The version of Zebra BioDome described here is penetrable, meaning that at room
197 temperature, the gel matrix is semi-solid – solid enough to prevent loss of the reaction mix, but
198 soft enough to be pierced with a standard pipette tip. Users only need to remove the adhesive
199 film and pipette the lysate into the reaction tube. A standard volumetric pipette with a
200 disposable tip (avoiding very narrow tips to prevent gel matrix blockage) is used to insert the
201 sample/control to the bottom of the Zebra BioDome tube. Once the pipette tip touches the
202 bottom, the pipettor is slightly withdrawn to allow dispensing of the lysate within the primer
203 mix layer. The pipette is then removed and visually inspected to ensure no clogging of residual
204 liquid in the tip. If clogging occurs, the volume transfer of 10 μ L lysate is repeated into the same
205 Zebra BioDome tube.

206 The gel matrix melts during amplification at 60°C enabling the mixing of the reaction
207 components and re-solidifies at the top of the reaction during cooling, thus creating a physical
208 barrier for the amplified products (Figure 1C-ii) and resulting in a sealed reaction chamber.

209 ***Statistical analysis***

210 Valid ScreenFire HPV results were obtained for 427 out of 450 samples for both the standard
211 and Zebra BioDome versions, which were included in the analysis. The remaining 23 were
212 excluded from the analytical sample because of invalid results on either or both assay versions
213 (7 invalids by Zebra BioDome, 7 invalids by standard, 9 invalids by both).

214 Analyses were done to assess the repeatability of Zebra BioDome when testing on two different
215 Powergene instruments and to compare the HPV results of Zebra BioDome to those of the
216 standard assay version.

217 Two types of analyses were conducted. First, channel-by-channel in a non-hierarchical fashion,
218 acknowledging that a sample could test positive for multiple HPV channels. Then, hierarchically
219 using the risk-based grouping of HPV genotype channels intrinsic to ScreenFire’s design. In the
220 hierarchical analysis, HPV results were categorized as HPV16 positive, otherwise positive for

221 HPV18/45 (if HPV16 was not detected), otherwise positive for HPV31/33/35/52/58 (if
222 HPV16/18/45 were not detected), otherwise positive for HPV39/51/56/59/68, and otherwise
223 negative for the 13 high-risk types.

224 Positive and negative agreement statistics were calculated, with 95% confidence intervals (CI)
225 estimated under normal approximation. Agreement statistics for the repeatability analysis were
226 calculated based on either replicate positivity/negativity. Agreement statistics for the
227 comparison of Zebra BioDome against the standard version were calculated using the standard
228 assay version as the reference. Additionally, McNemar's test for asymmetry was computed for
229 the channel-specific analysis. The analyses were adjusted back to the original sample by
230 weighting HPV negatives (i.e., 100 negatives were weighted by 9.41 for 941 negatives in the
231 original sample) while retaining channel-specific estimates.

232 Discrepancies between the Zebra BioDome version and the standard version were investigated
233 by examining PCR and Luminex results, as well as histopathology and LBC results when
234 available. Data on valid histopathology and/or LBC were available for 409 samples and both
235 missing for 18 samples. A reference case was defined as HPV16/18/45/31/33/35/52/58 PCR
236 positive for high-grade cervical intraepithelial neoplasia grade 2 or worse (CIN2+) on
237 histopathology or LBC, and in addition HPV16 PCR positive for low-grade/equivocal lesions on
238 histopathology or LBC. A reference control was defined as PCR high-risk HPV negative and
239 neither histology nor LBC positive. Following these definitions, we identified 29 definite cases
240 and 206 definite controls. 174 fell between the definitions of definite cases/controls.

241 Sensitivity analyses were carried out by restricting to HPV results of the study population of
242 women within the age range of 25 to 49 years.

243 All analyses were carried out using Microsoft Excel, the Statistical Package for the Social
244 Sciences (SPSS) (version 1.0.0.1089), and R Statistical Software (version 4.3.0).

245

246 **Results**

247 ***Repeatability***

248 There was excellent agreement between the two replicates of ScreenFire HPV testing with the
249 Zebra BioDome version on Powergene instrument 1 vs instrument 2 across all channels in the
250 non-hierarchical analysis (Table 1). The replicate on instrument 2 showed a slight, but non-
251 significant, increase in positivity compared to that on instrument 1 for the HPV31/33/35/52/58
252 channel. Repeatability was excellent also in the hierarchical analysis (not shown).

253 ***Channel-specific agreement***

254 The number of invalid results was similar when using Zebra BioDome and the standard assay
255 version of the ScreenFire assay: 7 invalids by Zebra BioDome, 7 invalids by standard, 9 invalids
256 by both. Among the 427 valid results by both, there was very good agreement between the
257 Zebra BioDome version and the standard version across all channels in the non-hierarchical
258 analyses (Table 2). Zebra BioDome showed a slight, but non-significant, increase in positivity
259 compared to the standard version for the HPV16 and HPV31/33/35/52/58 channels.
260 Conversely, the standard version exhibited a slight, but non-significant, increase in positivity for
261 the HPV39/51/56/59/68 channel. Additional positives detected by either version of the assay
262 did not show specific cross-reactivity patterns with other high-risk or low-risk HPV types
263 identified by PCR except for the possible chance finding that three of the seven additional
264 positives by Zebra BioDome for HPV31/33/35/52/58 were positive for HPV53. The two
265 additional positives by Zebra BioDome in the HPV16 channel were positive for HPV16 by either
266 PCR or Luminex. Similar agreement in the channel-specific analysis was found when repeating
267 the analysis only on the age range of 25 to 49 years and when using the results of the Zebra
268 BioDome replicate on Powergene instrument 2 (not shown).

269 ***Hierarchical agreement***

270 There was excellent agreement between the Zebra BioDome version and the standard version
271 of the ScreenFire assay also in the hierarchical analyses (Table 3), which is relevant for risk-
272 based clinical management. Following the hierarchical distribution of HPV channels by the

273 standard version, Zebra BioDome detected 25 out of 25 (100%) HPV16 positives; 24 out of 25
274 (96.0%) HPV18/45 positives in the absence of HPV16; 88 out of 90 (97.8%) HPV31/33/35/52/58
275 positives in the absence of HPV16, or 18/45; 35 out of 36 (97.2%) otherwise
276 HPV39/51/56/59/68 positives. The overall agreement between the Zebra BioDome version vs
277 the standard version was 97.2% (95% CI: 95.6%-98.8%) without sampling weights and 99.1%
278 (95% CI: 98.6%-99.6%) with sampling weights (Table 3). Similar agreement in the hierarchical
279 analysis was found when repeating the analysis using the results of the Zebra BioDome
280 replicate performed on Powergene instrument 2 (not shown).

281 Among the 29 reference cases, both the Zebra BioDome and the standard versions of the
282 ScreenFire assay detected 27 cases. Both versions missed the same two (6.9%) cases: one
283 positive for HPV16 and one positive for HPV31/33/35/52/58 by PCR.

284 Among the 206 reference controls, 13 (6.3%) were positive on both the Zebra BioDome and the
285 standard versions of the ScreenFire assay. The Zebra BioDome version identified an additional
286 three positives in the HPV31/33/35/52/58 channel.

287

288 **Discussion**

289 Our results showed that the Zebra BioDome version of the ScreenFire HPV RS assay had
290 excellent repeatability and agreement with the standard version of the assay, for each of the
291 four type groups defined by the assay individually and hierarchically. Small differences in
292 channel positivity and invalid results were seen but none were statistically significant.

293 The validation presented here aimed at comparing the novel Zebra BioDome version of
294 ScreenFire HPV RS assay with the established standard version of the assay and assessing its
295 repeatability on stored clinician-collected specimens under ideal laboratory conditions. A real-
296 life trial of the clinical performance of Zebra BioDome post-shipping under realistic simpler
297 laboratory conditions is beyond the scope of this work and is being addressed in ongoing field
298 evaluation.

299 The Zebra BioDome version of the ScreenFire HPV RS assay was designed to manage the reality
300 of HPV testing in LMICs, which is the need for accurate, rapid tests that allow single-day
301 screening strategies for cervical cancer. As compared to the standard version of the ScreenFire
302 HPV assay (8,9), Zebra BioDome seems to offer several advantages given its formulation with
303 pre-aliquoted reagents and an anti-contamination component.

304 First, it eliminates the need for master mix preparation and aliquoting, hence reducing the
305 number of manual pipetting steps. This translates into reduced hands-on time for assay
306 preparation and reduced variability due to potentially unequal manually pipetted volumes (i.e.,
307 unequal volumes of primer mix and reaction mix combined during preparation of master mix,
308 and/or unequal volumes of master mix dispensed in the reaction wells). The only manual
309 pipetting step is the addition of 10 μ L of lysate to the Zebra BioDome tube.

310 Second, the Zebra BioDome version reduces the risk of post-amplification contamination by
311 sealing the products with the BioDome matrix material. Contamination of amplified PCR
312 products in a molecular biology laboratory space is a critical concern, common to all PCR-based
313 techniques (13). The assay's high sensitivity means that even small amounts of DNA can be
314 amplified, leading to a high number of copies post-amplification with a risk of leakage.
315 Contamination is very damaging because it compromises the trustworthiness of results due to
316 false positives leading to incorrect interpretations and because it potentially invalidates the
317 entire laboratory due to the need to decontaminate and repeat experiments, wasting time and
318 resources. Separately from the work presented here, a few Zebra BioDome tubes were opened
319 post-reaction, swabbed from the inside and re-run with ScreenFire HPV assay. They were found
320 to have minimal to no amplification, thus demonstrating effective reduction of contamination
321 with amplified products. By reducing the risk of contamination, the BioDome matrix increases
322 the reliability of HPV results for clinical management. Besides the anti-contamination role, this
323 matrix also acts as stabilizer of the Zebra BioDome formulation because it separates the layers
324 of pre-aliquoted reagents (i.e., reaction mix and primer mix) avoiding their mixing and it creates
325 a barrier from the air in the tube.

326 The formulation of Zebra BioDome may present a versatile and cost-effective solution for a
327 wide range of DNA amplification techniques besides HPV, particularly at the table-top level. In

328 fact, the pre-aliquoted reagents and anti-contamination components are applicable to other
329 endpoint DNA amplification assays, potentially providing a broader application in research and
330 diagnostic settings. This innovation could prove instrumental in addressing generic problems of
331 molecular biology testing, such as assay preparation time and risk of post-amplification
332 contamination, and in advancing the accessibility of molecular testing in all settings where cost
333 and contamination control are critical.

334 The additional advantages of Zebra BioDome do not compromise those that are characteristic
335 of the ScreenFire HPV RS assay in its original formulation (8,9). Most importantly, the risk-based
336 hierarchy of HPV type channels because of the great difference in risk of cervical cancer
337 associated with HPV types (9). Hence, in case of positivity for multiple HPV channel, clinical
338 management is better directed following the hierarchical reading of the type groups: HPV16
339 positive, otherwise positive for HPV18 or HPV45 (if HPV16 was not detected), otherwise
340 positive for HPV31/33/35/52/58 (if HPV16/18/45 were not detected), otherwise positive for
341 HPV39/51/56/59/68, and otherwise negative. Like the standard version, the Zebra BioDome
342 version allows for detection of HPV and a human DNA control directly from clinical specimens
343 without the need for DNA extraction and is compatible with dry self-collected samples without
344 requiring collection media. It also allows for flexibility to run up to 96 samples/controls without
345 product wastage (i.e., the pre-aliquoted strips of 8-tubes can be used in multiples of 8 or cut as
346 needed). These optimizations do not translate in additional costs compared to the standard
347 version (approx. \$6 per test for scale-up). For transport and storage, the space requirement is
348 approximately unchanged while the temperature should be kept cold (recommended 2-8°C). A
349 note of caution goes for the transportation conditions because high temperatures may cause
350 disruption of the layers and invalidate the use of the product due to premature mixing of
351 reagents, hence the importance of maintaining a cold chain and implementing temperature
352 checks for this penetrable version of Zebra BioDome. In the future, a re-formulation may be
353 considered to allow greater stability at warm temperatures and to remove the need of cold
354 chain.

355 Following this positive evaluation, Zebra BioDome has been introduced at PAVE study sites
356 using ScreenFire HPV RS assay (12). This field-evaluation will address the assay's clinical
357 accuracy and will evaluate its real-world use across a wide range of laboratory settings.

358 **Conclusions**

359 In conclusion, the Zebra BioDome version of the ScreenFire HPV assay evaluated here has
360 demonstrated accurate risk-based genotype grouping while simplifying the HPV testing process
361 and reducing the risk of laboratory contamination. If validated in real-world settings, the assay
362 will be an example of a rapid HPV extended genotyping solution for resource-limited settings as
363 part of the ultimate public health goal to accelerate cervical cancer prevention. The formulation
364 may also have potential application for other DNA amplification assays.

365

366 **Additional details**

367 **Conflict of Interest:** The authors declare no conflict of interest. Atila BioSystems had no role in
368 the design, analysis, interpretation or drafting of this article.

369 **Funding source:** NCI Cancer Moonshot; NIH Intramural Research Program.

370 **Data availability statement:** The data that support the findings of our study are available from
371 the corresponding author upon reasonable request.

372 **Ethics statement:** Both Nigerian and National Cancer Institute (NCI, US) institutional review
373 boards (IRBs) (NCT 00804466) approved the original study protocol that included consent for
374 specimen storage for future research.

375 **Authors contributions:** Conceptualization, Mark Schiffman, Silvia de Sanjosé, Kanan T. Desai,
376 Federica Inturrisi; methodology, Mark Schiffman, Kanan T. Desai, Silvia de Sanjosé, Federica
377 Inturrisi, Didem Egemen; formal analysis, Kanan T. Desai, Federica Inturrisi, Didem Egemen;
378 Itoju field investigation, Mark Schiffman, Kayode O. Ajenifuja, Clement A. Adepiti, Julia C. Gage,
379 Nicolas Wentzensen; resources, Mark Schiffman, Kayode O. Ajenifuja, Clement A. Adepiti,
380 Nicolas Wentzensen; data curation, Kayode O. Ajenifuja, Julia C. Gage, Clement A. Adepiti,
381 Kanan T. Desai; laboratory evaluation, Amanda C. Hoffman, Casey L. Dagnall; writing—original

382 draft preparation, Kanan T. Desai, Mark Schiffman, Silvia de Sanjosé, Federica Inturrisi;
383 writing—review and editing, all. All authors have read and agreed to the published version of
384 the article.
385

386 References

- 387 1. International Agency for Research on Cancer. World Health Organization. GCO Cancer
388 Today. 2021. Available from: <https://gco.iarc.fr/today/>
- 389 2. World Health Organization. Global strategy to accelerate the elimination of cervical
390 cancer as a public health problem. 2020. Available from:
391 <https://www.who.int/publications/i/item/9789240014107>
- 392 3. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical
393 cancer prevention, second edition. Geneva: World Health Organization. 2021.
- 394 4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus
395 and cervical cancer. *Lancet*. 2007 Sep;370(9590):890–907.
- 396 5. de Sanjosé S, Serrano B, Tous S, Alejo M, Lloveras B, Quirós B, et al. Burden of Human
397 Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and
398 58. *JNCI cancer Spectr*. 2018 Oct;2(4):pky045.
- 399 6. Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al. A study
400 of type-specific HPV natural history and implications for contemporary cervical cancer
401 screening programs. *EClinicalMedicine*. 2020 May;22:100293.
- 402 7. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No.100B. Lyon,
403 France: World Health Organization. 2012.
- 404 8. Desai KT, Adepiti CA, Schiffman M, Egemen D, Gage JC, Wentzensen N, et al. Redesign of
405 a rapid, low-cost HPV typing assay to support risk-based cervical screening and
406 management. *Int J cancer*. 2022 Oct;151(7):1142–9.
- 407 9. Inturrisi F, de Sanjosé S, Desai KT, Dagnall C, Egemen D, Befano B, et al. A rapid HPV
408 typing assay to support global cervical cancer screening and risk-based management: a
409 cross-sectional study. *Int J cancer*. 2024 Jan;154(2):241–50.
- 410 10. Hou J, Belinson JL, Du H, Li C, Zhang W, Zhang L, et al. AmpFire HPV and ScreenFire RS
411 HPV validation trial. *Am J Clin Pathol*. 2024 Jun;161(6):535–42.
- 412 11. Mungo C, Guliam A, Chinula L, Inturrisi F, Msowoya L, Mkochi T, et al. Comparison of the
413 ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical
414 precancer among women living with HIV in Malawi. *Infect Agent Cancer*. 2024
415 May;19(1):24.
- 416 12. de Sanjosé S, Perkins RB, Campos N, Inturrisi F, Egemen D, Befano B, et al. Design of the
417 HPV-automated visual evaluation (PAVE) study: validating a novel cervical screening
418 strategy. *Elife*. 2024 Jan;12.
- 419 13. Borst A, Box ATA, Fluit AC. False-positive results and contamination in nucleic acid
420 amplification assays: suggestions for a prevent and destroy strategy. *Eur J Clin Microbiol
421 Infect Dis*. 2004 Apr;23(4):289–99.
- 422 14. Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, et al. The age-
423 specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural
424 Nigeria: implications for screen-and-treat strategies. *Int J cancer*. 2012 May;130(9):2111–
425 7.
- 426 15. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, et al. Comparisons of
427 HPV DNA detection by MY09/11 PCR methods. *J Med Virol*. 2002 Nov;68(3):417–23.
- 428 16. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al. High load

429 for most high risk human papillomavirus genotypes is associated with prevalent cervical
430 cancer precursors but only HPV16 load predicts the development of incident disease. Int
431 J cancer. 2007 Dec;121(12):2787–93.
432

433 **Tables**

434

435 **Table 1: Channel-specific repeatability of Zebra BioDome version of ScreenFire HPV RS assay,**
 436 **run on Powergene1 and Powergene2, amongst 426[#] samples with valid results**

Zebra BioDome ScreenFire HPV results: Powergene instrument 1/instrument 2	+/+ (N)	-/+ (N)	+/- (N)	-/- (N)	Overall positive agreement [95% CI]	Overall negative agreement [95% CI]	McNemar p-value
HPV16	27	0	0	399	100%	100%	NA [*]
HPV18/45	26	0	0	400	100%	100%	NA [*]
HPV31/33/35/52/58	103	3 ^a	7 ^b	313	91.2% [85.9%-96.4%]	96.9% [95.0%-98.8%]	0.34
HPV39/51/56/59/68	35	4 ^c	3 ^d	384	83.3% [72.1%-94.6%]	98.2% [96.9%-99.5%]	1.00
Agreement on overall HPV positivity (high-risk 13), irrespective of channel	175	5	6	240	94.1% [90.7%-97.5%]	95.6% [93.1%-98.2%]	1.00

437

438 [#]Excluding invalids on either replicate

439 ^{*}McNemar test statistic cannot be derived because the disagreement is zero

440 ^aThree positives on PCR: one for HPV58 (signal strength=2), one for HPV35 (signal strength=2), one for HPV52 (signal strength=2)

442 ^bThree positives on PCR: one for HPV35 (signal strength=3), one for HPV31 (signal strength=1), one for HPV58 (signal strength=2)

444 ^cTwo positives for HPV68 (signal strength=4 and 5) on PCR

445 ^dOne positive for HPV68 (signal strength=3) and one positive for HPV51 (sign strength=1) on PCR

446

447 **Table 2: Channel-specific agreement (non-hierarchical) between Zebra BioDome (run on**
 448 **Powergene1) and the standard version of ScreenFire HPV RS assay amongst 427 samples with**
 449 **valid results by both versions**

ScreenFire HPV results: Zebra BioDome (Powergene instrument 1)/Standard	+/+ (N)	-/+ (N)	+/- (N)	-/- (N)	Positive agreement with standard as reference [95% CI]	Negative agreement with standard as reference [95% CI]	McNemar p-value
HPV16	25	0	2 ^a	400	100%	99.5% [98.8%-100%]	0.48
HPV18/45	25	1 ^b	1 ^b	400	96.2% [88.8%-100%]	99.8% [99.3%-100%]	1.00
HPV31/33/35/52/58	104	1 ^c	7 ^d	315	99.0% [97.2%-100%]	97.8% [96.2%-99.4%]	0.08
HPV39/51/56/59/68	38	5 ^e	0	384	88.4% [78.8%-98.0%]	100%	0.07
Agreement on overall HPV positivity (high-risk 13), irrespective of channel	174	2	8	243	98.9% [97.3%-100%]	96.8% * [94.6%-99.0%]	0.11

450
 451 ^aOne of the two was positive for HPV16 on Luminex; the other was positive for HPV16 on PCR (signal
 452 strength=2)
 453 ^bAdditional positives on Zebra BioDome or standard version were positive for HPV18 on PCR (signal
 454 strength=2-3)
 455 ^cOne Positive for HPV31 on PCR (signal strength=2)
 456 ^dFour positives on PCR: one for HPV52 (signal strength=1), one for HPV35 (signal strength=2), two for
 457 HPV58 (signal strength=2); three additional were positive for HPV53
 458 ^eThree positives on PCR: two for HPV68 (signal strength= 4-5), one for HPV59 (signal strength=3)
 459 * Overall negative agreement was 96.8% [94.6%-99.0%] without sampling weights and was estimated to
 460 be 99.3% [98.8%-99.8%] after applying sampling weights for negatives.
 461

462 **Table 3: Hierarchical agreement between Zebra BioDome and the standard version of**
 463 **ScreenFire HPV RS assay according to HPV risk groups amongst 427 samples with valid results**
 464 **by both versions**

ScreenFire HPV results: Zebra BioDome (Powergene instrument 1)/Standard		Standard					Total for Zebra BioDome
		HPV 16	else HPV 18/45	else HPV 31/33/35/52/58	else HPV 39/51/56/59/68	else high- risk 13 negative	
Zebra BioDome	HPV16	25	0	1	0	1	27
	column%	100%	0%	1.1%	0%	0.4%	6.3%
	else HPV18/45	0	24	0	0	1	25
	column%	0%	96.0%	0%	0%	0.4%	5.9%
	else HPV31/33/35/52/58	0	1	88	0	6	95
	column%	0%	4.0%	97.8%	0%	2.4%	22.2%
	else HPV39/51/56/59/68	0	0	0	35	0	35
	column%	0%	0%	0%	97.2%	0%	8.2%
	else high-risk 13 negative	0	0	1	1	243	245
	column%	0%	0%	1.1%	2.8%	96.8% *	57.4%
Total for standard	25	25	90	36	251	427 **	

465
 466 Highlighted in gray are concordant HPV risk group results.

467 * Overall negative agreement was 96.8% without sampling weights and 99.3% after applying sampling
 468 weights for negatives.

469 ** Overall agreement was 97.2% without sampling weights and 99.1% after applying sampling weights for
 470 negatives.


471

472 **Figures**


473

474 **Figure 1: Steps to run the ScreenFire HPV RS assay on the Powergene instrument using dry**
 475 **swab samples following the PAVE study protocol (12). A) Assay in its standard liquid version**
 476 **(the blue box highlights the steps impacted by the introduction of Zebra BioDome).** B) Assay
 477 **in the novel Zebra BioDome version. C) Details of the Zebra BioDome version before (i) and**
 478 **after (ii) amplification.**

479



480



481